Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza zaawansowanego raka jajnika, raka wyrostka otrzewnej lub raka jajdunek
- •Wcześniejsze leczenie, które nie działało - widoczne na zdjęciach rentgenowskich
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG 0-1)
- •Prawidłowa funkcja organów wewnętrznych i szpiku kostnego
- •Rak jajnika oporny na platynę (wcześniejsze leczenie zawierające platynę nie zadziałało)
✗ Disqualifies
- •Duża operacja lub poważna uraz w ostatnie 4 tygodnie
- •Alergia na leki biologiczne, doksyrubicynę lub składniki badanego leku
- •Inny nowotwór wymagający aktualnego leczenia
- •Przerzuty do mózgu lub opon mózgowych bez leczenia
- •Nieskontrolowane infekcje, w tym HIV, wirusowe zapalenie wątroby B lub C
- •Duża ilość płynu w brzuchu
- •Niedrożność jelit w ostatnie 3 miesiące lub potrzeba specjalnego żywienia przez kroplówkę
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (54)
The University of Alabama at Birmingham
Birmingham, United States
UC San Diego Health
La Jolla, United States
Cedars Sinai Medical Center
Los Angeles, United States
Mayo Clinic Jacksonville
Jacksonville, United States
University of Miami Sylvester Comprehensive Cancer Center
Miami, United States
Advent Health Cancer Institute
Orlando, United States
Tampa General Hospital Cancer Institute
Tampa, United States
University of Chicago
Chicago, United States
The University of Kansas Cancer Center
Westwood, United States
Norton Cancer Institute, St. Matthews Clinic
Louisville, United States
Massachusetts General Hospital
Boston, United States
Karmanos Cancer Institute
Detroit, United States
The Ohio State University Comprehensive Cancer Center
Hilliard, United States
Providence Cancer Institute
Portland, United States
University of Pittsburgh Medical Center, Magee-Womens Hospital
Pittsburgh, United States
West Penn Hospital of Allegheny Health Network
Pittsburgh, United States
Avera Cancer Institute Sioux Falls
Sioux Falls, United States
UT Southwestern Medical Center
Dallas, United States
Swedish Cancer Institute
Seattle, United States
University of Wisconsin
Madison, United States
Medical College of Wisconsin
Milwaukee, United States
CancerCare Manitoba
Winnipeg, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Centre de Santé et de Services Sociaux de la Montérégie-Centre
Greenfield Park, Canada
Research Institute - McGill University Health Centre
Montreal, Canada
Centre Hospitalier Universitaire (CHU) de Quebec - Universite Laval
Québec, Canada
National Cancer Center
Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Keimyung University Dongsan Hospital
Daegu, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Asan Medical Center, Univ. of Ulsan
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Changhua Christian Hospital
Changhua, Taiwan
Chi Mei Medical Center
Tainan, Taiwan
Mackay Memorial Hospital
Taipei, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Taipei Municipal Wan Fang Hospital
Taipei, Taiwan
Medicalpark Seyhan Hospital
Seyhan, Turkey (Türkiye)
Hacettepe University
Altındağ, Turkey (Türkiye)
Medipol University Hospital
Istanbul, Turkey (Türkiye)
Gaziantep Medicalpoint Hospital
Gaziantep, Turkey (Türkiye)
Baskent University
Adana, Turkey (Türkiye)
Sbu Doctor Abdurrahman Yurtaslan Ankara Onkoloji Suam
Ankara, Turkey (Türkiye)
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Memorial Ankara Hospital
Ankara, Turkey (Türkiye)
Cerrahpasa Medical Faculty At Istanbul University Cerrahpasa
Istanbul, Turkey (Türkiye)
Izmir Ekonomi Universitesi (IEU) Medical Point Izmir Hastanesi (Izmir Economy University Medical Point Izmir Hospital)
Izmir, Turkey (Türkiye)
Sakarya University - Education and Research Hospital
Sakarya, Turkey (Türkiye)
Trial contact
Clinical Trials Administrator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.